

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	10,450 participants

Key Eligibility Criteria

Inclusion (8)

- Have Lp(a) ≥ 175 nanomoles per liter (nmol/L)
 - Meet one of the following criteria:
 - Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 years prior to screening
 - Are at risk for a first ASCVD event, defined as one or more of the following:
 - Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a history of ASCVD event
- ... and 3 more (see full listing online)

Exclusion (7)

- Have experienced a major cardiovascular event or surgery, such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body, within 90 days prior to screening or occurring between screening and randomization
 - Are planning or expected to undergo a procedure to restore blood flow in the arteries or a major heart surgery during the study
 - Have uncontrolled high blood pressure
 - Have New York Heart Association (NYHA) class III or IV heart failure
 - Have undergone a procedure to remove cholesterol from the blood within 90 days of screening, or have a planned procedure during the study
- ... and 2 more (see full listing online)

Locations (750 total)

Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert, Arizona, United States
Axsendo Clinical Research - Peak Heart & Vascular - Phoenix, Phoenix, Arizona, United States
Clinical Research Institute of Arizona (CRI) - Sun City West, Sun City West, Arizona, United States
... and 747 more locations